Document Detail

Insights into the future of gastric acid suppression.
MedLine Citation:
PMID:  19713987     Owner:  NLM     Status:  MEDLINE    
The development of effective acid-suppression therapy (particularly PPIs) has revolutionized the treatment of acid-related diseases. Despite the overall effectiveness of these agents, they have some shortcomings, including a delayed onset of action, incomplete acid suppression in the majority of patients, and the need for ingestion before a meal to achieve maximal efficacy. Attempts to overcome these issues have included the development of isomeric PPIs (such as esomeprazole), alterations in drug delivery (such as delayed-release dexlansoprazole), and combined therapy with nonenterically coated PPIs and antacids (such as 'naked' omeprazole combined with sodium biocarbonate). Other acid-suppression agents in development or in late-phase trials include potassium-competitive acid blockers, new histamine receptor 2 antagonists, and gastrin antagonists. Although these agents could potentially achieve complete gastric acid suppression, risks may be associated with this level of suppression, including enteric infections and malabsorption of nutrients such as vitamin B(12), iron and calcium. This Review provides an update on the status of acid-suppression therapy and discusses directions for future research.
Kenneth R DeVault; Nicholas J Talley
Related Documents :
9478067 - Duodenal gastric metaplasia, gastric anatomic-functional correlations (parietal cell ma...
9934577 - Diversion colitis--new light through old windows.
9748647 - Catabolic fate of dietary trilinoleoylglycerol hydroperoxides in rat gastrointestines.
314697 - Kinetics of acetylsalicylate and d-lactate transport across isolated frog gastric mucosa.
11170027 - Nasal absorption of tyrosine-linked model compounds.
24151907 - Flavor of cold-hardy grapes: impact of berry maturity and environmental conditions.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature reviews. Gastroenterology & hepatology     Volume:  6     ISSN:  1759-5053     ISO Abbreviation:  Nat Rev Gastroenterol Hepatol     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-28     Completed Date:  2009-11-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500079     Medline TA:  Nat Rev Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  524-32     Citation Subset:  IM    
Department of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32233, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Ulcer Agents / pharmacology,  therapeutic use
Gastric Acid / metabolism*
Gastroesophageal Reflux / drug therapy,  metabolism
Histamine H2 Antagonists / pharmacology*,  therapeutic use
Peptic Ulcer / drug therapy,  metabolism
Proton Pump Inhibitors / pharmacology*,  therapeutic use
Reg. No./Substance:
0/Anti-Ulcer Agents; 0/Histamine H2 Antagonists; 0/Proton Pump Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms of growth impairment in pediatric Crohn's disease.
Next Document:  Does PPI therapy predispose to Clostridium difficile infection?